1. Home
  2. Live Updates
  3. Metastatic renal cell carcinoma

Live Breaking News & Updates on Metastatic renal cell carcinoma

Stay informed with the latest breaking news from Metastatic renal cell carcinoma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Metastatic renal cell carcinoma and stay connected to the pulse of your community

Immunotherapy Before Noon Linked to Improved Survival in mRCC

Results are consistent with the authors' prior findings on the possible effects of circadian rhythm on outcomes after immunotherapy.

Georgia , United-states , Database-consortium-risk-score , International-metastatic , Icis-at-winship-cancer-institute , Emory-winship-cancer-institute-in-atlanta , Winship-cancer-institute , Image-credit , Consortium-risk-score , Immunotherapy , Circadian-rhythm

Dr Xu on Treatment Sequencing Considerations in Metastatic Renal Cell Carcinoma

Wenxin (Vincent) Xu, MD, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma.

Wenxin-vincent-xu , Dana-farber-cancer-institute , Harvard-medical-school , Rcc , D , Metastatic-renal-cell-carcinoma , Belzutifan , Tki ,

Novel Combination Regimens Are Expanding the Prostate Cancer Treatment Paradigm

Marijo Bilusic, MD, PhD, highlights key points presented at the meeting, including considerations with PARP inhibitor combinations for patients with mCRPC, how disease characteristics factor into treatment selection for patients with hormone-sensitive prostate cancer, and more.

Florida , United-states , Miami , University-of-miami-miller-school-medicine , Sylvester-comprehensive-cancer-center , Marijo-bilusic , Science-summit , Miami-miller-school , Janaki-neela-sharma , First-and-later-lines-of-metastatic-urothelial-carcinoma , Metastatic-renal-cell-carcinoma

Nephrectomy Offers Potential PFS Benefit in mRCC Who Underwent Immune-Targeted Therapy

Nephrectomy was associated with a progression-free survival (PFS) benefit compared with immunotherapy alone in patients with metastatic renal cell carcinoma who received immunotherapy.

China , Nanchang , Jiangxi , First-affiliated-hospital-of-nanchang-university , Rcc-database-consortium , First-affiliated-hospital , Nanchang-university , Jiangxi-cancer-hospital , Jiangxi-provincial-people , Immunotherapy-in-gu-cancers , Immuno-oncology

Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma

1. Recurrence-free survival was significantly different between the adjuvant everolimus and placebo groups. 2. Grade 3 or higher adverse events were more frequent in the everolimus group with oral mucositis being the most reported within this treatment arm. Evidence Rating Level: 1 (Excellent) Study Rundown: Patients with renal cell carcinoma face a high risk of

United-states , Rating-level , Advanced-renal-cell , Between-apr , Everolimus , Immune-checkpoint-inhibitors , Kidney-cancer , Metastatic-renal-cell-carcinoma , Nephrology , Oncology , Renal-cell-carcinoma

Renal Cell Carcinoma Prognosis and Risk Stratification

Experts in the field of kidney cancer discuss the risk stratification process for renal cell carcinoma and its effect on prognosis.

Advanced-kidney-cancer-treatment-landscape , Cell-carcinoma-prognosis , Kidney-cancer , Renal-cell-carcinoma , 5-year-survival , Renal-cell-carcinoma-prognosis , Kidney-cancer-prognosis , Kidney-cancer-risk-stratification , Kidney-cancer-staging , Metastatic-kidney-cancer , Kidney-cancer-recurrence

Atezolizumab added to cabozantinib does not improve clinical outcomes in patients with metastatic renal cell carcinoma

1. Progression-free and overall survival was comparable in both the intervention and control groups. 2. Serious adverse events were more common among patients taking a combination of atezolizumab-cabozantinib than cabozantinib-only. Evidence Rating Level: 1 (Excellent) Study Rundown: Immune checkpoint inhibitors are first-line therapy for patients with metastatic renal cell carcinoma (MRCC); however, optimal management for

Rating-level , Advanced-renal-cell , Between-jul , Atezolizumab , Cabozantinib , Immune-checkpoint-inhibitors , Kidney , Kidney-cancer , Metastatic-renal-cell-carcinoma , Oncology , Renal-cell-carcinoma

Study improves prediction of therapy response in patients with metastatic renal cell carcinoma

Study improves prediction of therapy response in patients with metastatic renal cell carcinoma
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Bonn , Nordrhein-westfalen , Germany , Jonas-saal , Institute-for-experimental-oncology , Outcome-predictions , On-treatment-modified-glasgow-prognostic-score , Cohort-on-treatment , University-hospital-bonn , Experimental-oncology , Medical-clinic , Glasgow-prognosis-score

Discoveries & Impact (February 2023)

Discoveries & Impact highlights select scientific discoveries across the Department of Internal Medicine...

Burnham , Connecticut , United-states , South-korea , Colombo , Western , Sri-lanka , Han , America , American , Kimg-smolderen , Mario-strazzabosco

Investegate |Ipsen Pharma Announcements | Ipsen Pharma: Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma

Investegate announcements from Ipsen Pharma, Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Chile , Japan , Saclay , France-general- , France , Shanghai , China , Santiago , Regióetropolitana , United-states , Paris , California